

FIBROGEN INC  
Form 8-K  
December 18, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 14, 2015**

**FibroGen, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36740**  
**(Commission**  
  
**File Number)**  
**FibroGen, Inc.**

**77-0357827**  
**(IRS Employer**  
**Identification No.)**

Edgar Filing: FIBROGEN INC - Form 8-K

**409 Illinois Street**

**San Francisco, CA 94158**

**(Address of principal executive offices, including zip code)**

**(415) 978-1200**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Director Resignation

On December 14, 2015, Miguel Madero provided notification of his resignation from FibroGen, Inc. (the Company) Board of Directors (the Board) effective December 31, 2015. Mr. Madero's resignation as a director is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Mr. Madero joined FibroGen's Board in 1995, and served in a number of capacities during his tenure with the Company. The Company is extremely grateful for his service over the past two decades and wishes him the best in his future endeavors.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 18, 2015

**FIBROGEN, INC.**

By: /s/ Michael Lowenstein

Michael Lowenstein  
Vice President, Legal Affairs